Compare CRWS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRWS | HURA |
|---|---|---|
| Founded | 1957 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 35.5M |
| IPO Year | N/A | N/A |
| Metric | CRWS | HURA |
|---|---|---|
| Price | $3.00 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 28.5K | ★ 1.5M |
| Earning Date | 02-11-2026 | 03-31-2026 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,751,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.35 | $0.41 |
| 52 Week High | $4.55 | $4.77 |
| Indicator | CRWS | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 67.34 | 54.80 |
| Support Level | $2.95 | $0.42 |
| Resistance Level | $3.03 | $0.75 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 94.44 | 99.58 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.